Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
This study collected patients used Lapatinib-base therapy among MBC, and tried to figure out if there was difference between single anti-Her2 treatment and dual anti-Her2 treatment. Furthermore, this study investigated the treatment after Lapatinib.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients who were treated with Lapatinib between June 2014 to June 2018.
Patients experienced progression on prior trastuzumab-containing regimens and a taxane.
Complete medical history was available.
You may not be if
Medical history was incomplete.
Clareo Health | Real World Study of Lapatinib Among Metastatic Breast Cancer Patients
